Journal
JOURNAL OF HEPATOLOGY
Volume 40, Issue 6, Pages 993-999Publisher
ELSEVIER
DOI: 10.1016/j.jhep.2004.02.007
Keywords
hepatitis C virus; genotype 2 and 3; treatment duration; steatosis
Categories
Ask authors/readers for more resources
Background/Aims: Treatment duration in patients with chronic hepatitis C in the era of standard interferon-alpha plus ribavirin was tailored according to hepatitis C virus (HCV) genotype: patients infected with HCV-1 were treated for 48 weeks, patients infected with HCV-2/3 for 24 weeks. The aim of the present study was to investigate this schedule for HCV-2/3 infected patients in the era of pegylated interferon-alpha plus ribavirin. Methods: Patients chronically infected with HCV-2 (n = 42) or HCV-3 (n = 182) were treated with peginterferon alfa-2b 1.5 mug/kg subcutaneously once weekly plus ribavirin 800-1400 mg/day based on body weight for 24 weeks. Results: The end of treatment (EOT) and sustained virologic response (SVR) was higher in patients infected with HCV-2 (100 and 93%, respectively) than in patients infected with HCV-3 (93 and 79%, respectively). Baseline viremia (P = 0.020), treatment duration > 16 weeks (P < 0.001) and steatosis (< 5 %, P = 0.015) were significant independent predictors of SVR. Adverse events resulted in discontinuation in 5% and dose reduction in 22% of patients. Conclusions: Treatment for 24 weeks with peginterferon alfa-2b and ribavirin is sufficient in HCV 2 or 3 infected patients. The lower SVR in patients infected with HCV-3 compared with HCV-2 infected patients may be related to higher levels of steatosis in this population. (C) 2004 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available